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Abstract
Background: Studies on Health Related Quality of Life (HRQoL) of chronic liver patients were
performed in clinical populations. These studies included various disease stages but small variations
in aetiology and no transplanted patients. We performed a large HRQoL study in non-cirrhotic,
cirrhotic and transplanted liver patients with sufficient variety in aetiology. We compared the
generic HRQoL and fatigue between liver patients and healthy controls and compared the disease-
specific and generic HRQoL and fatigue between non-cirrhotic, cirrhotic and transplanted liver
patients, corrected for aetiology.
Methods: Members of the Dutch liver patient association received the Short Form-36, the Liver
Disease Symptom Index and the Multidimensional Fatigue Index-20. Based on reported clinical
characteristics we classified respondents (n = 1175) as non-cirrhotic, compensated cirrhotic,
decompensated cirrhotic or transplants. We used linear, ordinal and logistic regression to compare
the HRQoL between groups.
Results: All liver patients showed a significantly worse generic HRQoL and fatigue than healthy
controls. Decompensated cirrhotic patients showed a significantly worse disease-specific and
generic HRQoL and fatigue than non-cirrhotic patients, while HRQoL differences between non-
cirrhotic and compensated cirrhotic patients were predominantly insignificant. Transplanted
patients showed a better generic HRQoL, less fatigue and lower probabilities of severe symptoms
than non-cirrhotic patients, but almost equal probabilities of symptom hindrance.
Conclusions: HRQoL in chronic liver patients depends on disease stage and transplant history.
Non-cirrhotic and compensated cirrhotic patients have a similar HRQoL. Decompensated patients
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show the worst HRQoL, while transplanted patients show a significantly better HRQoL than
cirrhotic and non-cirrhotic patients.
Background
In the year 2000, 40.9% of the Dutch population suffered
from a chronic disease. In that same year, more than 800
Dutch men and women died of a chronic liver disease
(0.6% of year specific total mortality) [1]. Until today, the
Dutch liver patient association (Nederlandse Lever-
patiënten Vereniging (NLV)) and many other patient
associations fight for recognition of disease related physi-
cal, mental and social problems of chronic patients. Qual-
ity of life research could contribute to a better
understanding of these problems and may fulfil this quest
for recognition.
One of the first studies done on Health Related Quality of
Life (HRQoL) of chronic liver patients was conducted in
1979 and studied the effect of liver transplantation on
HRQoL of chronic liver patients [2]. The study demon-
strated that the quality of life of liver patients after trans-
plantation ranged from poor to superior. In 1998, Foster
et al compared the HRQoL of liver patients with viral hep-
atitis B and C and reported that social functioning, energy
and fatigue and role limitations due to physical problems
were significantly more impaired in hepatitis C patients
[3]. In more recent studies, the HRQoL of different stages
of liver disease were compared. Younossi et al found an
increasing impairment of generic HRQoL with increasing
disease severity, while Marchesini et al found that the
most relevant determinants of impaired health status were
severity of disease and muscle cramps [4-6].
These studies contributed substantially to our knowledge
of the physical, social and mental problems of chronic
liver patients. However, the majority of these studies was
conducted in relatively small clinical populations and the
comparisons between disease stages were adjusted for
small or few aetiological groups. Moreover, none of these
studies included liver transplant recipients in the study
population.
Therefore, to get a better understanding of the differences
in HRQoL between the various disease stages and the rela-
tion with transplanted liver patients, one must study a
large liver patient population with a broad variety with
respect to disease stage and aetiology. Furthermore, the
HRQoL should be measured by a generic as well as a dis-
ease-specific questionnaire to give a profound insight in
the differences in HRQoL between disease stages [7,8].
Our study offers an extensive overview of the HRQoL of
chronic liver patients. In contrast to the clinical popula-
tions in earlier studies, our collaboration with the Dutch
liver patient association (NLV) gave us the opportunity to
study the HRQoL of large number liver patients,
approaching a population level. The study population of
1175 members included various stages of cirrhosis and
aetiologies as well as a large number of transplanted liver
patients. It provided us with sufficient varied information
to realise an HRQoL comparison between non-cirrhotic,
compensated cirrhotic, decompensated cirrhotic and
transplanted liver patients, corrected for aetiology.
Another distinguishing feature of this study is that the
HRQoL information was generated by means of the Liver
Disease Symptom Index 2.0 (LDSI), the Short Form-36
(SF-36) and the Multidimensional Fatigue Index-20 (MFI-
20). Other studies already used a combination of a generic
and a disease-specific questionnaire [4,5]. However, the
LDSI provides, in contrast to other liver disease-specific
questionnaires, information about the severity of symp-
toms and hindrance of these symptoms during daily activ-
ities. In an earlier study we demonstrated that the LDSI
provides additional information on top of the SF-36 and
the MFI-20 (S.M. van der Plas, unpublished). The SF-36
and MFI-20 were both validated in a clinical chronic liver
patient population [9]. Therefore, the combination of
these instruments forms a reliable and valid method to
accomplish the following aims:
1) To compare the generic HRQoL and fatigue between
chronic liver patients and healthy Dutch controls and 2)
to evaluate the differences in disease-specific HRQoL,
generic HRQoL and fatigue between non-cirrhotic, com-
pensated cirrhotic, decompensated cirrhotic and trans-
planted liver patients, corrected for aetiology. By
evaluating the differences in disease-specific HRQoL, we
addressed the known groups validity of the LDSI across
the various subgroups. The known groups validity is
based on the principle that certain specified groups of
patients, may be anticipated to score differently from oth-
ers. We evaluated whether the LDSI was sensitive to these
differences.
Methods
Study population
In October 2000, all 2020 members of the NLV were
approached for participation in this study and received a
questionnaire by mail. The members included patients
with a (history of) liver disease as well as non-patients
who joined the NLV because of involvement with liver
patients in family, circle of acquaintances or work. AfterBMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/33
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two months, non-responders received a new question-
naire. We closed the response period 5 months after the
first mailing. As requested by the Ethics Committee, mem-
bers gave their informed consent by confirming their will-
ingness to participate in the first question of the
questionnaire.
Inclusion criteria were: 1) Informed consent, 2) having a
(history of) liver disease and 3) aged 18 years or older at
the moment of administration. To preserve the anonym-
ity of the participants, the NLV withheld the coding of
respondent numbers and member names, while the
researcher withheld the completed questionnaires. The
protocol was conform the ethical guidelines of the 1996
Declaration of Helsinki and has been approved by the
Ethics Committee of the Erasmus Medical Centre Rotter-
dam, the Netherlands.
Measurement Instruments
The disease-specific LDSI 2.0 includes 18 items. Nine
items measure the severity of: 'Itch', 'Joint pain', 'Pain in
the right upper abdomen', 'Sleepiness during the day',
'Worry about family situation', 'Decreased appetite',
'Depression', 'Fear of complications' and 'Jaundice'. Nine
other items measure the hindrance of these symptoms
during daily activities. All items have 'the last week' as
time frame and are scored on a 5-point scale ranging from
'not at all' to 'to a high extent'.
Apart from the LDSI, 6 additional items recommended by
the NLV, were scored on the same 5-point scale. These
items concerned: 'Memory problems due to liver disease',
'Change of personality due to liver disease', 'Hindrance in
financial affairs due to liver disease', 'Involuntary change
in use of time personality due to liver disease', 'Decreased
sexual interest' and 'Decreased sexual activity'. The LDSI as
well as the extra NLV items have recently been validated in
chronic liver patients and showed a good feasibility, test-
retest reliability and construct validity (Van der Plas,
unpublished).
The generic (Dutch) SF-36 version 1.2, includes 8 multi-
item scales on Physical Functioning, Role limitations due
to Physical problems, Bodily Pain, General Health, Vital-
ity, Social Functioning, Role limitations due to Emotional
problems and Mental Health. The scale scores range from
0 to 100. A higher score indicates a better generic HRQoL.
SF-36 data of Dutch healthy controls was available [10].
The domain-specific MFI-20 includes five 4-item scales:
General Fatigue, Physical Fatigue, Reduction in Activity,
Reduction in Motivation and Mental Fatigue and scale
scores range from 4 to 20. Higher scores indicate more
fatigue. MFI-20 data of Dutch healthy controls was avail-
able [11]. Both the SF-36 and the MFI-20 proved to be reli-
able and valid in Dutch chronic liver patients [9].
A separate questionnaire was used to determine sex, age,
marital status, education level, aetiology, duration of the
liver disease, status of the liver disease(s) (cured, non-
cured), presence of a liver transplant, presence of cirrho-
sis, presence or history of splenomegaly, ascites or
oesophageal variceal bleedings, presence of oesophageal
variceal bleedings or ascites in the year 2000, history of
complications of cirrhosis (liver cancer or imminent
coma), comorbidity (defined as the presence of diseases
or disorders other than the liver disease that limit the
respondent's daily functioning), medication use and the
amount of hours per week spent on work and activities
with and without physical effort.
Liver patient comparison groups
Due to the design of the study, respondents originated
from all over the country and participated anonymously.
Therefore, we based the categorisation of respondents in
disease stage groups (non-cirrhotic (NC), compensated
cirrhotic (CC), decompensated cirrhotic (DC)) or the liver
transplant group (LTX) on reported clinical characteristics
(table 1).
Furthermore, we categorised respondents in 5 aetiology
groups based on reported aetiologies: Viral Hepatitis,
Autoimmune Hepatitis, Cholestatic diseases, Hemochro-
matosis and other liver diseases. Transplanted respond-
ents and respondents who considered themselves as cured
were respectively assigned to the groups 'Liver transplants'
and 'Cured liver diseases'.
We have validated the reliability of reported clinical char-
acteristics, disease stage definitions and reported aetiolo-
gies in a pilot study conducted at our Hepatology
outpatient clinic. Reported clinical characteristics and
aetiologies demonstrated a good agreement between the
test and the retest questionnaire (clinical characteristics: κ
0.85 [0.71, 0.94] to 0.97 [0.91, 1.03]; aetiologies: κ 0.71
[0.63, 0.79]) and a good agreement with hospital data
(clinical characteristics: κ 0.68 [0.45, 0.90] to 0.71 [0.53,
0.88]; aetiologies: κ 0.63 [0.55, 0.78]). Reported presence
of cirrhosis showed a moderate agreement with hospital
data (κ 0.52 [0.31, 0.73]). The assigned disease stage
groups showed a fair agreement with the disease stages
based on hospital data of the patients (κ 0.37 [0.19,
0.55]).
The hospital data revealed that our disease stage defini-
tions (which during the pilot did not include the criterion
of recent ascites or variceal bleeding), disregarded the tem-
porary state of the decompensated cirrhotic stage: patients
may become decompensated due to flare up of diseaseBMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/33
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activity or inflammation, but can reverse to an apparently
compensated state after treatment with beta-blockers, diu-
retics or (surgical) interventions.
During the current study, we took this temporary state of
decompensated cirrhosis into account by including the
criterion concerning: The presence of ascites or oesopha-
geal variceal bleedings in the year 2000 (the year of the
study), as extra item into the background questionnaire.
This extra criterion distinguished decompensated cir-
rhotic patients from reversed decompensated cirrhotic
patients. In the NLV population 43 compensated cirrhotic
were defined as reversed decompensated cirrhotic patients
(based on the absence of ascites and/or variceal bleedings
in the year 2000 and the use of diuretics and/or propa-
nolol at the moment of our study). The HRQoL level of
these patients fitted the HRQoL level of the compensated
cirrhotic group and not the HRQoL level of decompen-
sated patients. This indicated that these patients were cor-
rectly categorised as compensated cirrhotic patients.
Controls
Healthy Dutch controls for the SF-36 (n = 1715) origi-
nated from a nationwide, population based health status
survey with the standard version of the SF-36, conducted
by the Dutch Organisation for Applied Scientific Research
(TNO). Controls were adult members of a random sample
of Dutch households, drawn from the national telephone
registry. This registry included a somewhat larger percent-
age of men and a smaller category in the age of 15–25
years than the adult population in the Netherlands. TNO
corrected for this imbalance by stating in the introductory
letter that any adult member of the household could com-
plete the questionnaire. A random set of introductory let-
ters requested that the questionnaire had to be completed
by a member of the household between the ages of 15–25
years [10].
Healthy Dutch controls for the MFI-20 (n = 139) origi-
nated from a study on fatigue and radiotherapy in cancer
patients. Controls were adults from a non-selective sam-
ple of households taken from the telephone directories.
As women are more frequently at home, researchers of
this study prevented overrepresentation of women by
interviewing the next person to have a birthday within
that household [11].
Statistical Methods
We compared the generic HRQoL of NC, CC, DC and LTX
with the generic HRQoL of the general Dutch population.
SF-36 scale scores were calculated by SF-36 scoring algo-
rithms [12]. We estimated mean SF-36 scale scores by gen-
eral linear regression, in which we used the SF-36 scales as
dependent outcome. A variable, which included the dis-
ease stage groups, transplanted group and controls served
as independent determinant. Means were corrected for
sex, age, marital status and education level. Furthermore,
we compared fatigue between NC, CC, DC and LTX and
the general Dutch population. The MFI-20 scale scores
were calculated by MFI-20 scoring algorithms [13]. We
used general linear regression with the MFI-20 scales as
outcome to estimate mean MFI-20 scale scores. Again, the
variable that included the various subgroups served as
independent determinant. Means were corrected for sex,
age and education level.
To compare the generic HRQoL and fatigue between NC,
CC, DC and LTX, we performed a linear regression in SPSS
10.0 and in SAS 8.0. SF-36 scales or MFI-20 scales served
as dependent outcomes. Mean differences in SF-36 scale
scores or mean differences in MFI-20 scale scores were cal-
culated between NC (reference) and CC, DC and LTX. Of
each scale, model-based standard errors in SPSS were
compared with robust standard errors provided by PROC
MIXED using the 'empirical'-option in SAS 8.0. Model-
Table 1: Classification of disease stage groups and the transplanted group based on reported clinical characteristics.
Reported 
cirrhosis
Reported 
splenomegaly
Reported 
ascites
Reported variceal 
bleeding
Reported ascites and/or 
variceal bleeding in the 
year 2000
Transplant 
History
NC No No No No No No
CC Yes - - - No No
CC -Y e s - - N o N o
CC -- Y e s - N o N o
CC -- - Y e s N o N o
DC -- - - Y e s N o
LTX -- - - - Y e s
NC = Non-Cirrhosis, CC = Compensated Cirrhosis, DC = Decompensated Cirrhosis, LTX = Liver transplanted. Legend clinical characteristics: 
No: Absence of the clinical characteristic is an absolute condition for the concerning disease stage group or transplant group. Yes: Presence of the 
clinical characteristic is an absolute condition for the concerning disease stage group or transplant group. - : Presence or absence of clinical 
characteristic is no absolute condition.BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/33
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based standard errors in SPSS were similar as robust
standard errors in SAS.
We evaluated the known groups validity of the LDSI
symptom severity items across disease stages and the
transplanted group by means of a proportional odds
model for ordinal outcome with the PLUM procedure in
SPSS 10.0. In every LDSI symptom severity item, the mean
probability to score one of the five response categories (1
= 'no symptom' to 5 = 'severe symptom') was estimated
per disease stage group or transplant group. We used the
same model to evaluate the known groups validity of the
extra NLV items.
We evaluated the known groups validity of the LDSI
symptom hindrance items across disease stages and the
transplanted group by means of binary logistic regression.
We estimated for each subgroup the odds ratio of being
hampered by symptoms in daily activities (response cate-
gory 2 to 5), relatively to not being hampered (response
category 1) by these symptoms. We selected respondents
who actually had the symptom (symptom severity>1),
since we assumed that only those respondents could have
symptom hindrance.
Estimated differences, probabilities and odds ratios
between subgroups were corrected for gender, age, educa-
tion level, aetiology, use of liver disease medication, use of
psychofarmaca and comorbidity. Determinants were
regarded as significant when p < 0.05.
Results
Selection of the population
Of the 2020 members approached for this survey, 1617
members returned the questionnaires. Of these, 374
respondents were non-patient member, who joined the
NLV because of involvement with liver patients in family,
circle of acquaintances or work. In total 1243 patients had
a (history of) liver disease. According to the regulations of
the Ethics Committee, we excluded 21 patients who did
not give informed consent. Furthermore, we excluded
forty-seven patients younger than 18 years of age. In total
1175 respondents were included in the analysis. When we
assumed that the percentage of patient members was
equal in non-responders and responders (77%), than the
total number of patient members in the total NLV popu-
lation would be 1553 and the actual response (n = 1243)
would be around 80%.
Baseline characteristics
Table 2 shows the baseline characteristics of the study
population for non-cirrhotic, cirrhotic and transplanted
liver patients and the characteristics of Dutch healthy con-
trols for the SF-36 and the MFI-20. The total population of
1175 respondents, of which 678 (57.7%) women, had a
mean age of 48.6 years (SD ± 12.7, range 18–81). In total
76% of these respondents spent on average 24.5 (SD ±
16.3) hours per week on a paid and/or voluntary job and
spent on average 6.5 (SD ± 6.7) hours per week on physi-
cal activities like walking, cycling and gardening.
Table 2: Demographic and clinical characteristics of respondents.
Characteristic NC
(n = 489)
CC
(n = 391)
DC
(n = 84)
LTX
(n = 186)
Dutch SF-36 
controls
(n = 1715)
Dutch MFI-20 
controls
(n = 139)
Mean age ± SD, yr. 48 ± 12 49 ± 14 50 ± 12 49 ± 13 48 ± 17 46± 16
Gender
Men, n (%) 214 (43.8) 162 (41.4) 36 (42.9) 78 (41.9) 967 (56.6) 60 (44.4)
Women, n (%) 275 (56.2) 229 (58.6) 48 (57.1) 108 (58.1) 740 (43.4) 75 (55.6)
Education
None/elementary education 33 (6.8) 39 (10.0) 15 (18.1) 18 (9.7) 212 (12.6) 11 (8.1)
Lower secondary education 178 (36.5) 157 (40.2) 27 (32.5) 74 (40.0) 569 (33.8) 90 (66.7)
Upper/post secondary education 141 (28.9) 106 (27.1) 24 (28.9) 48 (25.9) 477 (28.4) 34 (25.2)
1st/2nd stage tertiary education 136 (27.9) 89 (22.8) 17 (20.5) 45 (24.3) 424 (25.2) 0 (0)
Marital status
Married / Living together 360 (73.9) 292 (75.1) 57 (67.9) 139 (75.1) 1278 (74.8)
Single / Widow(er) / Divorced 127 (26.1) 97 (24.9) 27 (32.1) 46 (24.9) 431 (25.2)
Aetiology
Viral hepatitis 169 (36.3) 77 (20.9) 23 (30.3)
Autoimmune hepatitis 51 (10.9) 77 (20.9) 11 (14.5)
PBC/PSC 76 (16.3) 84 (22.8) 13 (17.1)
Hemochromatosis 58 (12.4) 30 (8.2) 2 (2.6)
Other liver diseases 58 (12.4) 85 (23.1) 25 (32.9)
Liver diseases reported as cured 54 (11.6) 15 (4.1) 2 (2.6)
Liver transplants 186 (100)
For legend of disease stages, see table 1.BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/33
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All respondents with a liver transplant were assigned to
the liver transplant group (n = 186, 16.2%). The remain-
ing respondents were mainly non-cirrhotic (42.5%) and
compensated cirrhotic (34.0%). Twenty-five respondents
were not classified in one of the three disease stage groups
or in the transplant group because of missing values in the
classification items.
More than one-fifth of the 1175 respondents had viral
hepatitis (23.4%). Of the 54 (4.7%) respondents catego-
rised as missing, 23 respondents reported cirrhosis as their
liver disease, while 31 gave an unclear or insufficient
description of their liver disease.
Comparison of generic HRQoL and fatigue with Dutch 
healthy controls
Table 3 and 4 show respectively the generic HRQoL and
fatigue of chronic liver patients compared to Dutch
healthy controls. The majority of the chronic liver patients
reported a significantly impaired generic HRQoL and sig-
nificantly more fatigue compared to healthy controls.
Only transplanted liver patients showed a similar level of
mental health, bodily pain and reduction in motivation as
healthy controls.
Comparison of generic HRQoL and fatigue between non-
cirrhotic, cirrhotic and transplanted patients
Figure 1 shows the mean differences in SF-36 scale scores
between non-cirrhotic, cirrhotic and transplanted liver
patients. The generic HRQoL of chronic liver patients
worsened with a worsening disease stage. Non-cirrhotic
and compensated cirrhotic patients showed few signifi-
cant HRQoL differences. Patients with decompensated cir-
rhosis mostly demonstrated a significantly worse generic
HRQoL than non-cirrhotic patients. In contrast, trans-
planted patients scored on seven of the eight SF-36 scales
a significantly better HRQoL than non-cirrhotic patients.
Fatigue showed the same pattern across the disease stages
and the transplanted group (figure 2).
Known groups validity of the LDSI items
Figure 3a to 3i illustrate the known groups validity of the
LDSI symptom severity items. The probability to score
higher than 1 on itch, pain in the right upper abdomen,
Table 3: Mean SF-36 scores of Dutch healthy controls, non-cirrhotic, compensated cirrhotic, decompensated cirrhotic and transplanted 
liver patients.
SF-36 scale Dutch controls (CI 95%)
n = 1715
LTX (CI 95%)
n = 186
NC (CI 95%)
n = 489
CC (CI 95%)
n = 391
DC (CI 95%)
n = 84
PF 82 (81–83) 69 (66–72) 70 (68–72) 65 (63–67) 50 (66–72)
RP 75 (73–76) 53 (47–59) 48 (45–52) 44 (40–48) 21 (13–29)
BP 74 (73–75) 73 (69–76)* 66 (64–68) 64 (61–66) 48 (43–53)
GH 70 (69–71) 56 (53–59) 46 (44–48) 41 (39–43) 31 (26–35)
VI 67 (66–68) 62 (59–65) 51 (49–53) 50 (48–52) 39 (35–43)
SF 82 (81–83) 73 (69–76) 65 (63–67) 64 (61–66) 47 (42–52)
RE 80 (78–82) 74 (68–79) 67 (63–70) 63 (59–67) 49 (42–57)
MH 75 (74–76) 74 (71–76)* 67 (65–68) 67 (66–69) 61 (57–65)
For legend of disease stages, see table 1. Legend coding SF36 scales: PF=physical functioning, RP=Role limitations because of physical problems, 
BP=bodily pain, GH=general health, VI=vitality, SF=social functioning, RE=role limitations because of emotional problems, MH=mental health. 
Means are adjusted for gender, age, education level and marital status *) Not significantly different from the score in the general Dutch population.
Table 4: Mean MFI-20 scores of Dutch healthy controls, non-cirrhotic, compensated cirrhotic, decompensated cirrhotic and 
transplanted liver patients
MFI-20 scales Dutch controls (CI 95%)
n = 139
LTX (CI 95%)
n = 186
NC (CI 95%)
n = 489
CC (CI 95%)
N = 391
DC (CI 95%)
n = 84
GF 9.6 (8.7–10.4) 11.0 (10.3–11.8) 13.9 (13.3–14.2) 14.6 (14.1–15.1) 16.6 (16.0–17.7)
PhF 8.6 (7.7–9.4) 11.0 (10.2–11.7) 13.0 (12.6–13.4) 13.5 (13.0–14.0) 16.2 (15.2–17.3)
RA 8.5 (7.7–9.4) 10.1 (9.4–10.8) 11.5 (11.1–12.0) 11.7 (11.2–12.2) 14.3 (13.2–15.3)
RM 7.8 (7.2–8.7) 8.6 (8.0–9.3)* 10.5 (10.1–10.9) 10.5 (10.0–10.9) 12.4 (11.4–13.4)
MF 7.9 (7.0–8.7) 10.0 (9.3–10.7) 11.1 (10.6–11.5) 11.7 (11.2–12.2) 13.3 (12.3–14.5)
For legend of disease stages, see table 1. Legend coding MFI-20 scales: GF=general fatigue, PhF=physical fatigue, RA=reduction in activity, 
RM=reduction in motivation, MF=mental fatigue. Means are adjusted for gender, age and education level *) Not significantly different from the score 
in the general Dutch population.BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/33
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sleepiness, worry about the family situation, decreased
appetite, depression, fear and jaundice were highest for
liver patients with decompensated cirrhosis. These proba-
bilities were all significantly higher than the probabilities
of the non-cirrhotic group (p = 0.000 to p = 0.002). Prob-
abilities to score higher than 1 on joint pain were similar
for all disease stages. Compensated cirrhotic patients had
a significantly higher probability to score higher than 1 on
itch (p = 0.03), sleepiness (p = 0.014) and jaundice (p =
0.008) than non-cirrhotic patients. Transplanted liver
patients demonstrated significantly lower probabilities to
score higher than 1 on itch, joint pain, pain in the right
upper abdomen, sleepiness, worry about the family situa-
tion, decreased appetite, depression and fear of complica-
tions than non-cirrhotic patients (p = 0.000 to p = 0.002).
Figure 4 shows the known groups validity of the LDSI
symptom hindrance items. Decompensated cirrhotic
patients demonstrated for most symptoms significantly
higher odds ratios of symptom hindrance than non-cir-
rhotic patients. Compensated cirrhotic patients showed
only significantly higher odds ratios for hindrance of itch
during the day and during sleep and hindrance of
decreased appetite. Transplanted patients showed a signif-
SF-36 scale score differences between non-cirrhotic, compensated cirrhotic, decompensated cirrhotic and transplanted liver  patients Figure 1
SF-36 scale score differences between non-cirrhotic, compensated cirrhotic, decompensated cirrhotic and transplanted liver 
patients. For legend of disease stages see table 1. For coding of SF36 scales, see legend table 2. Differences are adjusted for 
gender, age, education level, aetiology, use of liver disease medication, use of psychofarmaca and comorbidity. *) Scale score of 
subgroup is significantly different from scale score of NC.
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icantly lower odds ratio of hindrance of depression than
non-cirrhotic patients.
Known groups validity of extra NLV items
Finally, we evaluated the known groups validity of the
extra NLV items. The analysis showed that decompen-
sated and compensated cirrhotic patients have a signifi-
cantly higher probability of memory problems than non-
cirrhotic patients (CC p = 0.009, DC p = 0.00), while
transplanted patients show a significantly lower
probability (p = 0.009). The probability of a change in
personality was, relatively to non-cirrhotic patients, only
significantly higher in the compensated and decompen-
sated patient group (CC p = 0.011, DC p = 0.000),
although transplanted patients showed a insignificant
higher probability compared to non-cirrhotic patients (p
= 0.093). Compared to non-cirrhotic patients only
decompensated patients showed significantly higher
probabilities of financial limitations as a result of the liver
disease (p = 0.000). Furthermore, the probability of
'involuntary change in use of time' increased significantly
with a worsening disease stage (CC p = 0.019, DC p =
0.000).
MFI-20 scale score differences between non-cirrhotic, compensated cirrhotic, decompensated cirrhotic and transplanted liver  patients Figure 2
MFI-20 scale score differences between non-cirrhotic, compensated cirrhotic, decompensated cirrhotic and transplanted liver 
patients. For legend of disease stages, see table 1. For coding of MFI-20 scales see legend table 3. Differences are adjusted for 
gender, age, education level, aetiology, use of liver disease medication, use of psychofarmaca and comorbidity. *) Scale score of 
subgroup is significantly different from scale score of NC.
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Transplanted patients showed the lowest probability that
the liver disease resulted in 'involuntary change in use of
time' (p = 0.000). The probabilities of decreased sexual
interest were not significantly different between trans-
planted, compensated cirrhotic and non-cirrhotic
patients, but decompensated cirrhotic patients showed a
significantly higher probability of decreased sexual
interest (p = 0.000). Decompensated as well as trans-
planted patients showed a significantly higher probability
of decreased sexual activity compared to non-cirrhotic
patients (DC p = 0.016, LTX p = 0.001).
Discussion
The aims of this study were: 1) the comparison of the
generic HRQoL and fatigue between chronic liver patients
and healthy Dutch controls and 2) to give a profound
insight in the differences in disease-specific HRQoL,
generic HRQoL and fatigue between non-cirrhotic, com-
pensated cirrhotic, decompensated cirrhotic and trans-
planted liver patients, corrected for various aetiologies.
We have shown that, even after correction for aetiology,
generic HRQoL, disease-specific HRQoL and fatigue wors-
ened with a worsening liver disease stage.
a-i: Probabilities per LDSI symptom severity item per response category, for all liver patient subgroups Figure 3
a-i: Probabilities per LDSI symptom severity item per response category, for all liver patients subgroups. For legend of disease 
stages, see table 1. Probabilities are adjusted for gender, age, education level, aetiology, use of liver disease medication, use of 
psychofarmaca and comorbidity. *)Probabilities of subgroup are significantly different from probabilities of NC.
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However, non-cirrhotic and compensated cirrhotic
patients mostly showed insignificant differences with
respect to generic and disease-specific HRQoL and fatigue.
Decompensated cirrhotic patients revealed a significantly
lower generic HRQoL, a higher probability of a worse
disease-specific HRQoL and more fatigue than non-cir-
rhotic patients. Transplanted liver patients demonstrated
a better generic HRQoL, a lower probability of severe
symptoms and less fatigue than non-cirrhotic and cir-
rhotic liver patients. However, their probability of symp-
tom hindrance was often not significantly different from
the non-cirrhotic group.
The worsening HRQoL across disease stages found in our
study, is in line with earlier studies [4-6,14]. Also Unal et
al infrequently found significant differences in generic
and disease-specific HRQoL and fatigue between non-cir-
rhotic and compensated cirrhotic patients, although the
trend across these two disease stages was reversed (com-
pensated cirrhotic patients showed a better HRQoL than
non-cirrhotic) compared to the trend found in our study
[9]. Even after we had analysed the Unal data with more
advanced statistical methods, corrected for factors like sex,
age, education and aetiology, the reversed trend
remained. It should however be noted that this study and
other earlier studies used different disease stage criteria
Odds ratios (OR) for symptom hindrance of transplanted and cirrhotic patients compared to non-cirrhotic patients Figure 4
Odds ratios (OR) for symptom hindrance of transplanted and cirrhotic patients compared to non-cirrhotic patients. For legend 
of disease stages, see table 1. *)Odds ratio of subgroup is significantly different from the NC group. Odds ratios are adjusted 
for sex, age, education level, aetiology, use of liver disease medication, use of psychofarmaca and comorbidity.
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(Child's-Pugh's score and histological data), which ham-
pered the inter-study comparison.
The results of the current study indicate that the LDSI has
a moderate to good known groups validity for the three
disease stages and the transplanted liver patient group.
The symptom severity items easily discriminated the
decompensated patients and the transplanted patients
from the non-cirrhotic patients. However, difficulties
occurred regarding the discrimination between compen-
sated cirrhotic and non-cirrhotic patients. The same prob-
lem emerged in the discrimination between compensated
and non-cirrhotic patients by the symptom hindrance
items.
It is unclear if these difficulties should be attributed to a
lack of sensitivity of the LDSI or to the natural characteris-
tics of the compensated cirrhotic disease stage. After all,
compensated cirrhotic patients may be asymptomatic for
years or decades: Ascites and neurological abnormalities
are often absent and in general these patients have a good
nutritional state. This may explain the similar HRQoL in
non-cirrhotic and compensated cirrhotic patients [6,15].
One study already demonstrated the absence of a signifi-
cant difference in HRQoL between these two groups in a
mixed population of chronic liver patients [14]. But a sig-
nificant difference between the disease-specific HRQoL of
non-cirrhotic and compensated cirrhotic was reported as
well, although this study only included cholestatic liver
patients [5]. Nevertheless, the LDSI items more frequently
distinguished between NC and CC patients than the
various SF-36 or MFI-20 scales, which illustrated the dis-
ease-specific character of the LDSI.
Until now, no other study directly compared the generic
and disease-specific HRQoL between transplanted liver
patients and non-cirrhotic and cirrhotic liver patients. Ear-
lier studies repeatedly demonstrated that post-trans-
planted liver patients have a much better HRQoL than
pre-transplanted liver patients [16,17]. However, our
study specifically revealed that transplanted patients also
have a better generic HRQoL and less fatigue than non-cir-
rhotic and cirrhotic liver patients. Nevertheless, the
HRQoL of transplanted patients was often significantly
impaired, compared to the HRQoL level of the general
population.
These results are in line with earlier research, which
revealed that transplanted liver patients do have some
physical problems, which indeed are experienced as
limitations in daily life. Although these limitations barely
seem to affect their overall HRQoL as transplanted
patients have minimum of concern about physical prob-
lems, the presence of limitations may explain the
impaired HRQoL of transplanted patients [18-22]. The
mental health of transplanted patients was comparable
with the mental health of the healthy controls, which con-
firms earlier literature stating that the tension, depression
and anger prevalence rates in transplanted patients were
not notably different from the rates in the general popula-
tion [23,18].
The high HRQoL of transplanted liver patients compared
to non-transplanted cirrhotic and non-cirrhotic patients
may be explained by the difference in acquired social sup-
port. Social support is of utmost importance as a resource
of coping with chronic illness and may be beneficial for
health outcome regardless of age [24,25]. For transplant
recipients the psychological support in the transplanta-
tion and rehabilitation period provided by medical staff
and family, is considered as one of the essentials of the
transplant program, as social support influences the post
transplantation survival and HRQoL [18,26]. However,
for other chronic liver patients the enhancement of social
support may be less considered as essential part of treat-
ment. Nevertheless, it could positively influence the
HRQoL by addressing negative feelings like low self-
esteem or hopelessness resulting from the irreversibility of
the pathological process and related disability. This
potential hiatus in chronic liver disease management
could be bridged by Social Network Mapping, which
establishes a dialogue regarding individuals' needs and
possible sources of support [27].
Despite of the fact that this study included a large popula-
tion of chronic liver patients, this study design also had
certain limitations. Since 90% of our respondents origi-
nated from The Netherlands, our study population could
be regarded as a selected population. In another quality of
life study conducted at our outpatient clinic, nearly a
quarter of the participants were not originally Dutch. Due
to the absence of other ethnic groups in our population,
extrapolation of our results to outpatient populations
should be done with caution.
Additionally, it is unclear which liver patients are attracted
by the patient association and how membership influ-
ences their HRQoL. Over representation of liver patients
with a low  HRQoL, seeking contact with other liver
patients may have led to an underestimation of HRQoL,
while other members' social support may have influenced
the measured HRQoL in our population positively. Fur-
thermore, we lacked information about non-responders
due to the design of the study. Therefore, responders may
have been a selection of relatively healthy patients who
felt well enough to complete the questionnaire, which
may have led to an overestimation of HRQoL.
A last possible limitation of this study is that we had to
depend on the respondents' knowledge with respect toBMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/33
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data about clinical symptoms and aetiologies. However,
our pilot study at the outpatient clinic demonstrated that
liver patients are very much aware of the clinical symp-
toms they have or have had and what type of liver disease
they suffer from. As we have no reason to expect that
members of a liver patient association are less informed,
we are confident that this population based study pro-
vided a reliable insight in the HRQoL of chronic liver
patients in Western countries.
Conclusions
We conclude that even after correction for aetiology, the
generic and disease-specific HRQoL and fatigue of chronic
liver patients depends on the patient's disease stage or
transplant history. Although the HRQoL worsened with a
worsening disease stage, non-cirrhotic and compensated
cirrhotic patients showed barely significant differences in
generic and disease-specific HRQoL or fatigue. Decom-
pensated cirrhotic patients showed a significantly worse
HRQoL compared to non-cirrhotic patients. The HRQoL
of transplanted patients exceeded the HRQoL of all other
chronic liver patients, although it was still impaired com-
pared to the HRQoL of healthy controls. Thus, chronic
liver patients cannot be considered as one group for
whom disease related problems have equal impact on
their daily functioning. For a good medical treatment and
an honest approach of chronic liver patients it is therefore
important that the disease stage or the transplant history
are taken into account. Enhancing social support given by
medical staff or family as part of chronic liver disease
management may partly close the HRQoL-gap between
chronic liver patients and transplanted liver patients.
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